Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by hmmmmmmmmon Oct 17, 2024 3:09pm
129 Views
Post# 36270435

RE:RE:RE:RE:I want to be a cheerleader for this company but…

RE:RE:RE:RE:I want to be a cheerleader for this company but…Good post BlueJay, you made me go to the way back machine to see if we can learn anything from the run up in 2016.

Spectral 2016:

 

Jan 11   Announce 400 of 446 were enrolled (90%)    SharePrice .79

 

Jan 12  A very favorable $2.50 target analysis by Mackie Research Capital Corp. (who coincidently also underwrote Spectral financing (with Cormark))    SP .80

 

Feb 24  Raise closes for 7.1M (US) to finalize trial.   SP .80

 

June 16 Spectral touts PMA acceptance.   SP .88

 

Jun 20th Announces completion of enrollment.   SP .88

 

June 27  Wins compassionate use exemption from FDA.  SP .95

 

July 4 Spectral announces plans to buy back up to 4.1 million shares.  SP $1.01 (continues to move up to $1.21 in July)

 

Sept 27 Closes at $1.86  the week before numbers released.

 

Oct 3rd Top line numbers released... 

If I'm missing anything please add. I know Dr Walker made his positive trial prediction in Sept. but I couldn't track down the date.

My takeaway is the price just creeped up with positive news/ enrollment. The first real movement came with the announcing the 4.1M share buy back. That "action" was a very loud "exceeding expectations!!". (In reality I can't see that they acutaly bought shares back- but it got the ball moving).
The largest jump was in the last 2 weeks before the numbers were to be released $1.13- 1.86. The power of old school, late money, fomo...

<< Previous
Bullboard Posts
Next >>